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ABSTRACT 
 
Small Molecule Inhibitors of the SARS-CoV Nsp15 Endoribonuclease, Mechanism of 
Action and Insight into Coronavirus Infection. (May 2009) 
Joanna Maria Ortiz Alcantara, B.S., National Autonomous University of Mexico 
Chair of Advisory Committee: Dr. Cheng C. Kao 
 
The Severe Acute Respiratory Syndrome (SARS) virus encodes several unusual 
RNA processing enzymes, including Nsp15, an endoribonuclease that preferentially 
cleaves 3’ of uridylates through a Ribonuclease A-like mechanism. Crystal structures of 
Nsp15 confirmed that the Nsp15 active site is structurally similar to that of Ribonuclease 
A. These similarities and our molecular docking analysis lead us to hypothesize that 
previously characterized Ribonuclease A inhibitors will also inhibit the SARS-CoV 
Nsp15.  Benzopurpurin B, C-467929, C-473872, N-36711, N-65828, N-103018 and 
Congo red were tested for effects on Nsp15 endoribonuclease activity. A real-time 
fluorescence assay revealed that the IC50 values for inhibiting Nsp15 were between 0.2 
µM and 40 µM.  Benzopurpurin B, C-473872, and Congo red are competitive inhibitors, 
according to kinetic studies and were demonstrated to bind SARS-CoV Nsp15 by a 
differential scanning fluorimetry assay. Benzopurpurin B also inhibited the Nsp15 
orthologs from two other coronaviruses: mouse hepatitis virus (MHV) and infectious 
bronchitis virus. The three compounds reduced infectivity of MHV in L2 cells by 8 to 26 
fold. The more effective drugs also caused a decrease in MHV RNA accumulation.  
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NOMENCLATURE 
 
SARS-CoV Severe Acute Respiratory Syndrome Coronavirus 
Nsp15 Nonstructural Protein 15 
RNase A                      Ribonuclease A 
MHV Mouse Hepatitis Virus 
IBV Infectious Bronchitis Virus 
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INTRODUCTION 
 
The Severe Acute Respiratory Syndrome (SARS) outbreak emerged in 
Southeastern China in 2002 and eventually spread to 30 countries by 2003. SARS was 
characterized by an atypical pneumonia transmitted primarily by contact with infectious 
respiratory droplets or fomites and it was responsible for 8096 confirmed cases with a 
mortality rate of about 10% (WHO). SARS is caused by the SARS coronavirus (SARS-
CoV) (1, 2, 3).  Horseshoe bats are the natural reservoir of SARS-CoV like viruses but 
they have been isolated also from palm civets and raccoon dogs from wild animal 
markets in China, suggesting that these mammals served as an amplification host and 
could be the source of infection in humans (4, 5, 6). The existence of a natural reservoir 
raises the possibility of a reemergence of SARS.  The treatment used during the 
epidemic consisted of corticoid steroids and ribavirin (1, 2, 3). In hindsight, some of 
these treatments had severe side effects and minimal efficacy (1, 2, 3). Currently there 
are no approved anti-virals against SARS (7), and specific therapeutic options will be 
needed to contain future outbreaks. 
SARS is a member of the group II Coronavirus within the order Nidovirales (8). 
Coronaviruses are enveloped and their positive-strand RNA genomes are the largest 
known, they are of interest in their mechanism of gene expression and replication. In this 
section, a general overview of the biology of coronaviruses will be presented, from their 
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taxonomy, morphology and genome organization to their viral replication cycle, 
including a summary of the proposed RNA synthesis and processing mechanisms and 
the proteins involved (for reviews of coronaviruses, see references 9-11). 
 
Biology of Coronavirus Infection 
Taxonomy  
The Coronaviridae family of enveloped RNA viruses is formed by two genera, 
the coronaviruses and the toroviruses, which together with the arteriviruses and 
roniviruses form the order Nidovirales. Members of the coronavirus family are divided 
in three groups, originally based on antigenic relationships, later by comparisons of the 
sequences of the entire viral genomes (12). Coronaviruses cause respiratory or intestinal 
infections. Most of the group 1 and group 2 coronaviruses infect mammals, and human 
coronaviruses are classified in these groups. Group 3 viruses have avian hosts only. 
Mouse hepatitis virus (MHV), human coronavirus OC43, and the bovine coronavirus are 
members of group 2, of which SARS-CoV according to rooted phylogenetic trees 
together with bat SARS-CoV form group 2b, and the infectious bronchitis virus is 
member of group 3 (8, 13). 
 
Virion morphology 
Coronaviruses are spherical, with virions of about 80-120 nm projecting club-
like, petal shaped surface spikes of 17-20 nm from the lipid envelope, and helical 
nucleocapsids according to negatively stained electron micrographs (14, 15).  
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Genome organization 
Coronaviruses have nonsegmented, single-stranded positive RNA genomes of 
about 30 kb, with 5’ caps and 3’ poly(A) tails; the largest among all RNA viruses. The 
SARS-CoV genome contains ~29730 nucleotides excluding the 3’ poly(A) tail. The 5’ 
and the 3’ untranslated regions contain 265 and 342 nucleotides respectively. The 
genome is predicted to have 14 functional open reading frames (ORFs). Two large, 5’-
terminal ORFs 1a and 1b form the replicase gene that encodes 16 nonstructural proteins 
including those required for viral RNA synthesis. The other twelve ORFs encode the 
structural proteins S, M, N and E and eight accessory proteins (16, 17, 18). 
 
Viral replication cycle and virion assembly 
Coronaviruses entry into target cells initiate with binding of the viral S (Spike) 
protein to cellular receptors. Trimers of the Spike protein decorate the virion surface like 
the spikes in a crown and inspired the name for this group of viruses. The Spike protein 
is heavily glycosylated and have three domains, the N-terminal S1, which is conserved 
and the C-terminal transmembrane and cytoplasmic S2 subdomains. The minimal 
binding domain of the SARS-CoV S protein was mapped to the residues 318-510 of S1 
and antibodies specific for this subunit neutralize SARS-CoV infection (19, 20). 
Aminopeptidase N, a zinc metalloprotease is the receptor of several group 1 
coronaviruses (21); carcinoembryonic antigen-related cell adhesion molecules are 
cellular receptors of MHV from group 2 (22) and the angiotensin-converting enzyme 2 
(ACE2), a metalloprotease expressed in the lung, intestine, liver, heart, vascular 
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endothelium, testis and kidney is the functional cellular receptor of SARS-CoV (23, 24). 
S1 binds to the cellular receptor triggering conformational changes that will co-localize 
the fusion peptide upstream of the two heptad repeats of S2 to the transmembrane 
domain to facilitate fusion of the viral and cellular membranes. SARS-CoV membrane 
fusion is activated within endosomes by cathepsin L proteolysis (25, 26).  
Following the fusion, the viral genome RNA is released into the cytoplasm of the 
infected cell, the mechanism involved in the RNA uncoating is not well understood. 
Genome expression of the SARS-CoV starts with the cap-dependent translation of the 
genomic RNA, mRNA 1, producing a 4382 amino-acid protein called polyprotein 1 
(pp1a) encoded by ORF 1a; then the 7073-residue polyprotein 1ab (pp1ab) encoded by 
ORFs 1a and b sequences is produced by ribosomal frameshifting. This occurs into the -
1 reading frame, just upstream of the ORF1a translation stop codon mediated by the 
signal of the slippery sequence 13392UUUAAAC13398 and a downstream RNA pseudoknot 
structure. Polyproteins pp1a and pp1ab are processed by viral proteinases into Nsp1-16 
to form the viral replicase-transcriptase multi-protein complex. In general, coronaviruses 
process the replicative polyproteins at the N-proximal regions at three sites using two 
papain-like proteases PL1pro and PL2pro. SARS-CoV uses only one papain-like protease, 
a PL2pro orthologue with narrow substrate specificity, containing a putative Zn-finger 
structure required for the proteolytic activity (18, 27, 28). The central and C-terminal 
regions of pp1a and pp1b are processed by the chymotrypsin-like protease 3CL pro, also 
called the coronavirus main protease, Mpro , that releases the RdRp and helicase, key 
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replicative functions. The SARS-CoV 3CL pro cleaves pp1a and pp1ab at 11 sites, as 
illustrated in Fig. 1 (18, 29, 30).  
 
 
 
FIGURE 1. Domain organization and proteolytic processing of SARS-CoV replicase proteins. Taken 
from Ziehbur J. (2004) Curr.  Opin.  Microbiol. (31).  
 
 
 
 
The viral replicase-transcriptase complex mediates the viral genome replication 
and the transcription of a nested set of eight subgenomic (sg) mRNAs, both require the 
synthesis of negative-strand intermediates. All the sg mRNAs have a 72-nucleotide, 5’-
terminal leader sequence identical to the 5’-end of the genome, and they are generated 
by discontinuous synthesis rather than full-length RNA transcription as supported by UV 
transcription mapping experiments in MHV-infected cells in which the size of a given 
mRNA was correlated to the target size for ultraviolet light irradiation for the synthesis 
of that mRNA (32) and principally by mixed infection experiments, in which the 
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reassortment of leader sequences was observed in the mRNAs produced  in cells infected 
with two different strains of MHV (33). The discontinuous synthesis of RNA depends on 
transcription-regulating sequences TRSs, cis-active RNA elements with the common 
core sequence ACGAAC for the SARS-CoV (18). There is currently consensus in the 
field about discontinuous transcription occurring during the synthesis of minus RNA 
strands. In the leader-primed transcription model the leader RNA is produced first, then 
transferred to the full-length minus strand, to the complementary TRS (34). In a second 
model, the nascent minus strand synthesis is paused at the TRSs and translocated to the 
leader TRS located downstream of the 5’-leader sequence on the genomic RNA, to 
continue the transcription. The minus-strand RNAs containing the anti-leader sequence 
are then used as templates for continuous plus-strand synthesis of sg mRNAs (35, 36, 
37). Complementary base-pairing and protein-protein interactions keep the 5’ end of the 
genome close to the site of minus-strand synthesis in both models. The negative-strand 
discontinuous transcription model is currently gaining favored status (37). The finding in 
infected cells of subgenomic minus strand RNAs with antileader sequence, subgenomic 
replicative-intermediate RNAs active for transcription for each mRNA (38, 39, 40) as 
well as the analysis of RNA synthesis using equine arterivirus full-length infectious 
cDNA in which mutations were introduced in the leader or body copies of TRS 
performed support this model (41, 42, 43, 44). The SARS-CoV structural proteins S, M, 
N and E, and eight additional proteins with unknown functions are predicted to be 
encoded in RNAs 2-9. mRNAs 2, 4, 5 and 6 are functionally monocistronic, mRNAs 3, 
7, 8 and 9 bicistronic, Fig. 2. (8, 18). 
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FIGURE 2. Genome organization and RNA synthesis of SARS-CoV. Taken from Ziehbur J. (2004) 
Curr. Opin Microbiol. (31).  
 
 
 
 
Coronaviruses likely attach the replication machinery to the membrane of 
autophagosomes forming double-membrane vesicles (9). The membrane bound 
structural proteins M, S, and E are inserted into the endoplasmic reticulum ER, then they 
transit to the endoplasmic reticulum-Golgi intermediate compartment ERGIC. When 
viral genomic RNA and structural proteins are accumulated, the N protein, the most 
abundantly expressed viral protein, encapsidate the progeny genomes forming 
nucleocapsids that interact with the membrane-bound proteins and bud into the ERGIC 
to form virions. Progeny virions are transported to the plasma membrane in vesicles or 
Golgi sacs not yet clearly defined to be exported out of the infected cell (9). 
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Proteins involved in RNA synthesis and processing 
The roles of many of the nonstructural proteins that assemble a membrane-
associated replicase-transcriptase complex are not completely elucidated. However, 
several have novel functions that are not found in smaller positive-strand RNA viruses 
(8). Included in these are proteins Nsp8, a putative RNA primase for Nsp12, the RNA-
dependent RNA polymerase; Nsp14, a 3’ to 5’ exoribonuclease that may serve 
proofreading functions; Nsp15, an endoribonuclease, and Nsp16 a putative  
methyltransferase  that acts on the ribose 2’ hydroxyl (45, 46, 47, 48).   
Nsp12 is the coronavirus RNA-dependent RNA polymerase (RdRp), it is 
predicted to have the fingers, palm and thumb domains characteristic of other viral and 
reverse transcriptases, and unique to coronaviruses a very large amino-terminal domain 
essential for activity and containing the segment responsible for the association of the 
RdRp with intracellular membranes. RdRp has been shown to associate with Mpro, Nsp8 
and Nsp9 (49, 50).  Nsp8 is a putative second RdRp unique to coronaviruses with 
specificity for the internal 5’-(G/U)CC-3’ trinucleotides on RNA templates to start the 
synthesis of complementary oligonucleotides of less than 6 nucleotides with low fidelity. 
It is proposed to produce primers for the Nsp12 RdRp (45). In this regard, Nsp8 is highly 
novel in acting as a RNA primase for a viral RNA-dependent RNA polymerase.  
Nsp13 is a helicase with multiple activities according to studies in HCoV-229E 
and SARS-CoV. It binds single and double-stranded RNA and DNA. It has NTPase and 
dNTPase activities, that are template-dependent, probably to provide the energy to 
translocate along the template.  It unwinds both DNA and RNA duplexes and is more 
9 
 
processive in a 5’-to-3’ direction, suggesting a role in the preparation of the template for 
RNA synthesis by the RdRp complex. It has RNA 5’-triphosphatase activity, proposed 
to participate in the 5’ cap synthesis on coronavirus RNA (51, 52, 53, 54). 
Nsp14 has exoribonuclease activity. It has been shown to act on the 3’ to 5’ 
direction on single and double-stranded RNA and requires divalent metal ions for its 
activity. It does not hydrolyze ribose-2’-O-methylated RNA or DNA substrates. Its 
ribonucleolytic activity is regulated by binding to the dsRNA. It is involved in viral 
RNA synthesis. Active site mutants of the human CoV 229E Nsp14 are defective in viral 
sgRNA synthesis, they present reduced genome replication and no viable virus can be 
recovered (46). 
Nsp15, the topic of this research, is an uridylate-specific endoribonuclease that 
will be described in detail later. 
Nsp16 is a putative 2’-O-methyltransferase (2’-O-MT), activity that is speculated 
to participate in RNA capping or in negative-strand RNA synthesis (8, 48).  
Nsp14-16,  with ExoN, Nendo U and 2’-O-MT activities respectively are located 
in a single protein block in pp1ab just next to the RdRp and helicase, suggesting that 
they may have concerted activities. Snijder et al. (8) proposed a parallel to two cellular 
RNA processing pathways. In one of them, Xendo U and ExoN participate in the 
cleavage of pre-mRNA to produce U16 and U86 intron encode small nucleolar RNAs 
(snoRNAs) that could be used in subsequent rRNA processing mediated by 2’-O- 
methylation and the 2’-O-MT activity. In the second, an ADP-ribose 1’’-phosphatase 
(ADRP) and a cyclic phosphodiesterase (CPD) present only in some group 2 
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coronaviruses but not SARS would be involved, in comparison to their cellular 
homologs that mediate the ADP-ribose 1’, 2’ cyclic phosphate processing to produce 
mature tRNA. However, the roles of the viral enzymes in a given pathway as well as 
their biological substrates are still elusive. It is interesting that although the ExoN, 
NendoU, 2’-O-MT and ADRP activities are conserved in all coronaviruses, just the 
NendoU is conserved in arteriviruses whose genomes are smaller, suggesting that given 
the extremely large genome of the coronaviruses, extra activities are required for RNA 
replication and transcription similar to DNA organisms but unprecedented for RNA 
viruses; as an example, it has been speculated that  ExoN could have a role in RNA 
proofreading and repair, activities not seen in RNA viruses, as well as recombination. 
These predictions still need to be proved experimentally (8). 
 
The SARS-CoV Nsp15 Endoribonuclease 
This section will summarize the features of the SARS-CoV Nsp15, required for 
its enzymatic activity, and the structural properties required for oligomerization and 
substrate recognition. 
Nsp15 has endoribonuclease activity. It cleaves at RNA uridylates, stimulated by 
Mn2+ as a cofactor, which could induce a conformational change in the protein according 
to measurement of changes in tryptophan fluorescence (47, 48). Later it was 
demonstrated that the cleavage occurs specifically at 3’ of uridylates, preferentially 
unpaired, with higher affinity for substrates with consecutive uridylate bases, and in the 
proper sequence context it can also cleave 3’ of cytidylates, and Mn2+ enhance RNA 
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binding (55). Upon cleavage of RNA molecules a 2’-3’ cyclic phosphate ended molecule 
is produced (48, 55). It has been named Nendo U and it is a genetic marker of 
nidoviruses that is not present in other RNA viruses (8, 48). It has similarities to Xendo 
U, an endoribonuclease from Xenopus laevis that participates in the processing of pre-
mRNA to produce small nucleolar RNAs. Xendo U is also uridylate-specific, Mn2+ 
dependent and generates products with 2’-3’ cyclic phosphate ends; besides the 
functional aspects both endoribonucleases have sequence similarities (8, 56, 57). Nsp15 
plays a role in viral replication and transcription as demonstrated in a study with a 
Human CoV 229E active site mutant in which viral RNA synthesis was abolished (48). 
Furthermore, in mutational studies in the Arterivirus Nsp15 ortholog, several active site 
mutants showed reduced plaque formation and virus titers (58). Similar observations 
were reported for MHV A59 (59). Nsp15 is not able to cleave 2’-O-ribose methylated 
RNA, suggesting a functional cooperation with Nsp14, a putative 2’-O-ribose 
methyltransferase. (48). 
The WT SARS-CoV Nsp15 was found to be in equilibrium between monomers, 
trimers and hexamers in solution. Only the hexameric form is enzymatically active (60). 
Transmission electron microscopy demonstrated that Nsp15 assembles into a hexameric 
structure formed by a dimer of trimers interacting end-to end, forming a narrow tunnel in 
the center and several channels. It is also the hexameric form that binds to RNA. The 
RNA binding to the outside of the hexamer, interacting with both trimers, was suggested 
by a low-resolution co-crystal of Nsp15 and RNA (55, 60). Crystal structures with one 
subunit in the asymmetric unit have been solved for SARS-CoV Nsp15 and its MHV 
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ortholog (61, 62). Six catalytic sites are exposed at the surface when a hexamer is 
assembled. The three catalytic residues His-234, His-249, Lys-289 located in the C-
terminal domain of the SARS-CoV Nsp15 resemble the catalytic triad His-12, Lys-41 
and His-119 found in Ribonuclease A and although superimposition of tertiary structures  
was impossible, the catalytic residues Lys-His-His of both enzymes were superimposed 
successfully (61), supporting previous mutational studies in which the residues His-234, 
His-249, Lys-289 and Asp-272 of SARS-CoV Nsp15 (60), and the corresponding 
residues His-His-Lys in the MHV ortholog (62) were required for ribonucleolytic 
activity, proving to have a direct role in catalysis, as it was suggested because they are 
highly conserved among members of the Xendo U family and coronavirus orthologs (8). 
Furthermore, mechanistic similarities between RNase A and Nsp15 are also conceivable, 
in RNase A, His-12 and His-119 have general base and general acid functions, and the 
pentacovalent intermediate is stabilized by the interaction of the phosphate moiety with 
Lys-41. In SARS-Co-V Nsp15 the position of the two catalytic histidines suggest they 
can accept and donate protons, and this is supported by the fact that Nsp15 cannot cleave 
DNA or 2’-O-methylated RNA where there is no 2’-OH to be deprotonated by His-249; 
for both enzymes 2’-3’ cyclic phosphate molecules are produced, see Fig. 3 (48, 55, 61, 
63).  
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FIGURE 3. Mechanism of action of Ribonuclease A. Taken from Roberts G. et al. (1969) PNAS (63). 
 
 
 
 
 
Of note the C-terminal tail of Nsp15 folds towards the active site suggesting that 
residues at that location could be important for substrate recognition and specificity (61). 
The elucidation of the structure of a SARS-CoV active-site mutant with six 
subunits in the asymmetric unit led to the prediction of residues required for subunit 
interaction, specificity in substrate recognition and RNA binding (64). The N-terminal 
residue E3, previously demonstrated to be involved in oligomerization, plays a role in 
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trimer-trimer interactions according to the crystal structure (60, 64). Residues N52, I26 
and I27, were also predicted to participate in trimer-trimer interactions. Interestingly, the 
mutants E3A, N52A, I26, 27A expected to form trimers eluted as monomers in gel 
filtration, suggesting that trimers are unstable intermediates. Consistent with hexamers 
being required for endoribonuclease activity, Nsp15 with mutations that prevented 
proper trimer-trimer interaction had endoribonuclease activity to less than 1% of WT.  
D39, R90, E266, participate in intratrimer interactions, and mutations in these residues 
in Nsp15 result in proteins that elute as monomers and show a significant reduction in 
endoribonuclease activity to less than 1% of WT. A N163A mutant, also expected to be 
affected on interactions between trimers, was found to form monomers and hexamers 
with nearly equal distribution, and to have 29% of the activity of WT (21). A molecular 
docking analysis with UMP revealed that some active site residues located in the C-
terminal tail could play a role in specificity and substrate recognition. S293, Y342, L345 
and P343 were predicted to be important. Previously Ricagno et al. (61) observed that 
superimposing RNase A and Nsp15 catalytic triads, the positions of S293  and Y342 of 
Nsp15 were comparable to those of T45 and F120 of RNase A that participate in 
pyrimidine specificity by forming  hydrogen bonds and van der Waals interactions with 
the base respectively. In the docking model, S293 could form H-bonds with the uracil, 
and the aromatic ring of Y342 could stack against the uracil while P343 and L345 are 
above it narrowing the pocket. The catalytic residues K289, H234 and H249 are 
positioned to interact with the ribose 2’ OH and the phosphodiester group as illustrated 
in Fig. 4 (64).  
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FIGURE 4. Molecular docking of UMP into the Nsp15 active site. Taken from Bhardwaj, et al. (2008) 
J. Biol. Chem. (64). 
 
 
S293, L345, P343 and Y342 were demonstrated to be important for catalysis 
since Nsp15 mutants of this residues showed either a reduction in endoribonuclease 
activity in comparison to WT, or inactivity (Y342A), while no alterations in the 
oligomerization state were observed. The role of S293 in specificity was established in a 
study in which mutants to A, N or T were constructed. All the mutants formed hexamers. 
In this study, S293T showed very low cleavage activity against cytidylates and 
uridylates in comparison to WT, S293N cleaved cytidylates and uridylates with strong 
preference for uridylates comparable to WT, while S293A presented similar rates of 
cleavage of cytidylates and uridylates and was not able to cleave purines, demonstrating 
that this residue is important to specifically recognize the substrate (64). P343 and L345 
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are also important for substrate recognition according to observations made in mutants 
of these residues that would have a wider pocket or a more flexible active site. P343G 
was showed to have reduced catalytic activity in comparison to WT and preference to 
cleave uridylates over cytidylates. L345G had reduced cleavage activity, with nearly 
equal preference for uridylates and cytidylates and interestingly it was able to cleave 
purines, confirming that this residue should sterically block the access of a purine in the 
WT catalytic pocket (64). In the same study, mutants H18A, T47A,N28/29A, N73A and 
K256A presented decreased RNA binding as well as the active site mutants Y342A and 
L345G, suggesting that these residues contribute to RNA binding (64). 
Ribonucleases are classified in two main groups. The ribonucleases in the first 
group include RNase H and RNase III, they depend on two metal ions, one to activate 
the substrate, the second to stabilize the transition state; they cleave 5’ of the cognate 
phosphodiester. The second group formed by members of the RNase A family and 
RNase T1 are independent of metal ions and cleave at 3’ of the cognate phosphodiester. 
Nsp15 shares characteristics of both groups, its activity is enhanced by Mn2+ and its 
mechanism of cleavage is similar to that of RNase A; it together with Xendo U define a 
novel family of endoribonucleases, endo U (65, 66, 67, 68). 
Nendo U is a promising target for developing antiviral drugs, given that is widely 
conserved among nidoviruses but absent in other RNA viruses, and it plays an important 
role in viral RNA synthesis. 
Compounds Benzopurpurin B, C-473872, C-467929, N-306711, N-103019 and 
N-65828 were previously described as inhibitors binding to the active site of angiogenin 
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and RNase A, by Kao, R. Y., et al. (69) and Jenkins, J. L., et al. (70). Congo red is an 
analog of Benzopurpurin B.  The structural and mechanistic similarities between SARS-
CoV Nsp15 and RNase A suggested that those compounds might inhibit the 
endoribonuclease activity of coronavirus Nsp15. 
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OBJECTIVES 
 
The present study is intended to determine whether small-molecule inhibitors of 
RNase A and Angiogenin, an RNase A–like enzyme, can affect enzymatic activity of the 
SARS-CoV Nsp15 endoribonuclease (sNsp15) in vitro and coronavirus infection in 
cultured cells. 
Specific aim 1: To investigate whether the selected small-molecule inhibitors of 
RNase A and Angiogenin are also able to inhibit the endoribonuclease activity sNsp15 
and to establish their mechanism of inhibition. A real-time fluorescence assay was used 
to study the efficacy of the compounds on the activity of purified sNsp15 in vitro. A gel-
based assay was used to confirm the results. To demonstrate binding of the compounds 
to sNsp15 differential scanning fluorimetry assays were performed. The mechanism of 
inhibition of the compounds was analyzed using kinetic studies.   
Specific aim 2: To test the effects of the selected small-molecule compounds on 
Nsp15 orthologs of other coronaviruses. The activity of the compounds on highly 
purified recombinant MHV and IBV Nsp15 orthologs was established by the real-time 
fluorescence assay. 
Specific aim 3: To examine the effect of the compounds on MHV infection in 
cultured cells and to investigate the effect of the compounds on viral RNA synthesis. 
Plaque assays were performed in L2 cells for MHV. Agarose gel electrophoresis of viral 
RNAs metabolically labeled in the presence of actinomycin D was used to study the 
effect of the compounds on the production of genomic and sub-genomic MHV RNAs. 
19 
 
MATERIALS AND METHODS 
 
Reagents 
 SARS and MHV Nsp15 His-tagged at the N termini, and IBV Nsp15 with an 
His-tag at both termini were expressed in E. coli and purified by metal ion affinity 
chromatography and Mono Q ion exchange chromatography as previously described 
(47). The proteins were stored in a buffer containing 50 mM Tris (pH 7.9), 300 mM 
NaCl, 1 mM dithiothreitol and 50% (v/v) glycerol at -20 °C. The protein concentrations 
were quantified by absorbance at 280 nm. Compounds N-306711, N-103019 and N-
65828 were obtained from the National Cancer Institute. C-473872 and C-467929 were 
purchased from ChemBridge Corp. Benzopurpurin B and Congo red were purchased 
from Sigma-Aldrich (St. Louis, MO). 
 
Molecular Modeling  
The molecular docking program Dock 6.0 was used to execute flexible docking 
of the energy minimized inhibitor into the wild type sNsp15 crystal structure (PDB ID 
2H85, (61)), which was kept rigid. A set of spheres that represent the negative image of 
the binding pocket was defined within the 10-Å radius of the sNSP15 catalytic-site 
residues H249, H234, K289, and Y342 to adopt the sphere-matching algorithm; 
incremental construction (anchor-and-grow method) was used to allocate the flexible 
conformations for the ligand. The automatic matching mode was used with 20 
configurations per ligand building cycle. Interaction between the ligand and the receptor 
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was evaluated by the grid score (a combination of van der Waals and electrostatic 
components) followed by visual inspection.  
Whether the inhibitor candidate could bind the MHV Nsp15 protein crystal 
structure (PDB ID 2GTH, (62)) over sNsp15 was analyzed by superimposing the latter 
docked with Benzopurpurin B over the former; for IBV a homology model was 
generated using Swiss-Model server (http://swissmodel.expasy.-
org/SWISSMODEL.html) and superimposed on sNsp15 docked with Benzopurpurin B.  
The figures were prepared using UCSF Chimera (http://www.cgl.ucsf.edu/chimera/).  
 
Endoribonuclease Assays 
A real time endoribonuclease assay was performed as previously described (55). 
The assay used a substrate named rU from Integrated DNA Technologies, Inc. 
(Coralville, Iowa) whose fluorescence is quenched until cleavage at the uridylate. 
Fluorescence was monitored in a Fluorostar Optima (BMG Inc.) at excitation and 
emission wavelengths of 492 and 518 nm, respectively.  
A gel-based RNA cleavage assay is used to confirm endoribonuclease activity 
and was performed as described previously (47). The 16-nt oligoribonucleotide substrate 
(GAAGCGAAACCCUAAG; Dharmacon Inc.) was labeled at the 5’ end with [γ-32P]-
ATP and T4 polynucleotide kinase.  Each reaction contained 10,000 cpm radiolabeled 
RNA substrate at a final concentration of 1 µM and 26 nM Nsp15 in Buffer T (50 mM 
Tris-HCl [pH 7.5], 50 mM KCl, 1 mM dithiothreitol and 5 mM MnCl2). The reactions 
were incubated at 30 °C for 30 min and terminated by adding the gel-loading buffer 
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containing 90% (v/v) formamide. Products were separated by electrophoresis in 7.5 M 
urea, 20% (w/v) polyacrylamide gels. Gels were wrapped in plastic, and radiolabeled 
bands were quantified using a PhosphorImager (Molecular Dynamics). 
 
Differential Scanning Fluorimetry  
Differential scanning fluorimetry was performed in an Eppendorf Mastercycler 
EP realplex machine. Each sample was prepared in a total volume of 50 µL containing 
solutions of SARS-CoV Nsp15 at 2.5 µM final concentration, SYPRO orange 
(Molecular probes) at 2.5 X final concentration, and inhibitor in buffer T (100 mM Tris 
[pH 7.0], 50 mM KCl and 5 mM MnCl2). The 96-well plate containing all of the samples 
was heated at a rate of 1.0 °C/min, from 25 to 95 °C, and the fluorescence intensity was 
measured with Ex/Em wavelengths of 470/550 nm. The Tm values were calculated by 
obtaining the maximum of the first derivative using Kaleidagraph (71).  Each sample 
was tested in triplicate, and the results were duplicated in at least two independent 
assays. 
 
Plaque Formation Assays 
 Mouse L2 cells were grown in DMEM with 10% serum medium in 6-well cell 
culture plates at 37 °C and 3% CO2 for 48 h or until 100% confluent. MHV A59 
dilutions (10-1 to 10-6) were prepared in DMEM without serum. Virus inoculum and 
inhibitor were incubated 15 min at 4 °C. Cells were infected and incubated 1 h at room 
temperature then covered with 3 mL of a mixture 1:1 of 2X DMEM 2% serum and 1.6 
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% agarose (equilibrated to 45 °C). Plates were incubated at 37 °C and 3% CO2 for 48 h, 
stained with a 1% crystal violet solution and the number of plaques formed was used to 
calculate the pfu/mL. Each inhibitor was tested at 100 µM in triplicate.  
 
Labeling of Viral RNAs 
L2 cells (2.25 x 105 per well) were seeded in 12-well plates and incubated at 37 
°C in CO2 incubator for 12 h. Cells were infected with MHV A59 at an MOI of 1 in the 
presence or absence of 100 µM inhibitor and further incubated for 6 h, washed twice 
with phosphate-free DMEM, fed with DMEM supplemented with 2 % dialyzed fetal 
bovine serum and actinomycin D (10 µg/ml) and incubated at 37 °C in CO2 incubator. 
After a 15-min. incubation, the medium was replaced with phosphate-free DMEM 
supplemented with 2% dialyzed serum, 10 µg/ml actinomycin D and 200 µCi/ml 32PO4. 
Cultures were further incubated at 37 °C in CO2 incubator for 5.5 h. The radiolabeled 
cultures were washed twice with ice-cold phosphate-buffered saline and RNA was 
extracted using an RNeasy mini kit (Qiagen). Purified RNA was mixed with 
formaldehyde gel-loading buffer containing ethidium bromide, incubated at 65 °C for 15 
min, chilled on ice and loaded onto a 1% formaldehyde-agarose gel. Electrophoresis was 
carried out at 100 V for 6 h. Following electrophoresis, the gel was illuminated with UV 
light and the image was captured with a BioDoc-It imaging system, and the relative 
amounts of 28S rRNA bands were determined by densitometry. The gel was then fixed 
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with 70 % methanol for 30 min, dried over vacuum and exposed to a PhosphorImager 
screen for quantification using Molecular Dynamics software. 
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RESULTS 
 
Computational Docking of RNase A and Angiogenin Inhibitors  
Compounds active against Ribonuclease A (70) and against Angiogenin (69), 
which have an Ribonuclease A active site, were selected for analysis against the SARS-
CoV Nsp15 protein. The structures of the compounds are shown in Fig. 5A and B.  We 
first formed a collaboration with Dr. S. Palanitathan of the Sacchettini laboratory to 
perform computational docking of the compounds into the structure of sNsp15 (PDB 
2H85). The goal of this study was to determine whether the compounds are sterically 
and electronically compatible with the active site structure of sNsp15. The results in this 
section are from Dr. S. Palanitathan.  
Small-molecule compounds N-65828, its analog Benzopurpurin B as well as two 
analogs of the compound C-181431, C-473872 and C-467929, and the compounds N-
306711 and N-103019 were all predicted to bind to the enzyme active site by 
computational docking (Fig. 5C and 1D). All these inhibitors are predicted to interact 
with the active site groove formed by the residues Y342, H234, H249 and K289 and two 
cavities at either side of the active site. The docking scores were better for the 
Ribonuclease A inhibitors (Benzopurpurin B, C-473872, and C-467929) than for the 
Angiogenin inhibitors (Fig. 5E). In fact, the RNase A inhibitors were predicted to fully 
utilize the active site and the associated cavities present on either side of it.  These 
results prompted us to also analyze the docking of Congo red, which is chemically 
similar to Benzopurpurin B except that it lacks the two methyl groups in the inner two 
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six-member rings, and this is expected to alter the conformation of the compound.  
Congo red had a slightly better docking score (-57.78) than Benzopurpurin B and was 
thus added to the compounds that we would test in functional assays.  
 
 
 
 
 
FIGURE 5. Small molecule inhibitors tested for effects on Nsp15. A, inhibitors of Ribonuclease A 
previously reported by Jenkins et al. (70). Congo red, a Benzopurpurin B analog was also assayed. B, 
inhibitors of Angiogenin previously reported by Kao et al. (69). C, the docking of Benzopurpurin B to the 
catalytic site of SARS-CoV Nsp15. The docking conformation with the higher score is shown. The C-
terminal active site groove is shown in a yellow ribbon representation under a semi-transparent surface 
colored by atom. The catalytic site residues are labeled. The inhibitor stacks with Y342 residue and 
occupies the entire C-terminal active site groove of sNsp15. D, the docking conformation of N-65828 in 
the sNsp15 catalytic site. E, docking scores of the inhibitors tested.  Panels C, D and E by Palaninathan S.  
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Effects of the Inhibitors on sNsp15 Endoribonuclease Activity  
A real-time fluorescence assay and highly purified recombinant sNsp15 protein 
were used to examine the efficacy of the inhibitors against sNsp15 in vitro (55).  All of 
the compounds showed a concentration-dependent inhibition of sNsp15 
endoribonuclease activity and an examination of the output of such an assay performed 
with Benzopurpurin B is shown in Fig. 6A.   
To confirm that the real time cleavage results are illustrative of an inhibition of 
RNA cleavage activity, the effects of the compounds on the cleavage of a previously 
characterized 16-nt RNA in a gel-based assay was performed. The results were found to 
be consistent with those from the real time assay (Fig. 6B). The remainder of the results 
presented will be from the real time assay.  
The concentration of inhibitors needed to reduce sNsp15 endoribonuclease 
activity by 50 and 90% (IC50 and IC90, respectively), were determined for each of the 
compounds used in the molecular docking reaction. Inhibitor titration experiments with 
Benzopurpurin B and Congo red are shown in Fig. 6C and a summary of all of the IC50 
and IC90s are shown in Fig.  6D. Of all the compounds tested, Benzopurpurin B was the 
best inhibitor, with IC50 and IC90 of 0.2 and 0.9 µM, respectively.  We also note that 
while functional examination of the effects of the inhibitors on endoribonuclease 
activities confirmed that the Ribonuclease A inhibitors were more effective than the 
Angiogenin inhibitors, the relative ranking of the results from two assays did not 
correspond.   
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FIGURE 6. Effects of the small molecule inhibitors on the SARS-CoV Nsp15 endoribonuclease 
activity. A, representative results of a real-time endoribonuclease assay showing the inhibitory effect of 
Benzopurpurin B at different concentrations on the sNsp15 activity. The slope of the change in 
fluorescence was used to determine the rate of cleavage by Nsp15. B, a demonstration of the results from a 
gel-based RNA cleavage assay in presence of increasing concentrations of Benzopurpurin B. C, 
Benzopurpurin B and Congo red titrations plots using the real-time endoribonuclease assay. Concentration 
dependent inhibition of the substrate cleavage by sNsp15 is shown. D, summary of the IC50 and IC90 
values for the small molecule compounds tested. 
 
 
 
 
 
Mechanism of Action of Select Inhibitors  
To demonstrate that the compounds could bind to the sNsp15, we tested for 
changes in Nsp15 in response to temperature.  The assays were performed using 
differential scanning fluorimetry in the presence of the dye SYPRO Orange, which binds 
to the hydrophobic regions of a protein that are exposed by temperature-induced 
unfolding.  The transition curves are complex, as would be expected by the unfolding of 
an oligomeric protein, however, a major peak could be readily identified (Fig. 7A). The 
temperature where there is a maximal transition in this peak will be designated the 
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Tmapp. All samples were tested in triplicate and in a buffer capable of supporting 
enzymatic activity that included 5 mM Mn2+, which we observed to help in smoothing 
the changes in transition, likely by affecting sNsp15 conformation, as previously 
demonstrated by Bhardwaj et al. (2004),  (47). The sNsp15 protein had a Tmapp at 49 oC 
in the absence of ligand. In the presence of Benzopurpurin B at 1, 3 and 5 µM final 
concentration, the Tmapp values were 49, 55 and 56°C respectively (Fig. 7B). A reaction 
performed in the absence of sNsp15, but in the presence of these concentrations of 
Benzopurpurin B or other inhibitors tested did not change the fluorescence of SYPRO 
orange.  The change in the Tmapp provides evidence for the interaction between the 
compounds and sNsp15. Compound C-473872 at 5, 10 and 20 µM also increased the 
Tmapp values in a concentration-dependent manner (Fig. 7B). Unexpectedly, while 
Congo red did cause a concentration-dependent change, there was decrease in the Tmapp.  
Given that the inhibitors were originally active site inhibitors of Ribonuclease A 
and Angiogenin, it is likely that they will act as competitive inhibitors of sNsp15. The 
inhibitory effects of Benzopurpurin B, Congo red, and C-473872 were tested at several 
concentrations, and the results from a minimum of three independent analyses were 
averaged and analyzed by a double reciprocal plot. The results are compatible with 
inhibition of SARS-CoV Nsp15 by a competitive mechanism (Fig. 7C). According to 
this mechanism the compounds are able to bind to the free enzyme active site, competing 
with the substrate. Because not all of the plots crossed at the zero in the axes, these 
results do not rule out the presence of additional ligand binding sites or that all of the 
active sites bind to the inhibitors in the same manner. In fact, crystal structure of the 
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Nsp15 revealed that there is a significant difference in the active sites of the six subunits 
of Nsp15 and that the difference is particularly distinct between the two trimers of 
Nsp15. 
 
 
 
 
 
 
FIGURE 7. Mechanism of inhibition of Nsp15 by select inhibitors. A, first derivative of the differential 
scanning fluorimetry assays for C-473872. A peak for each curve is obtained at the Tm. A shift of the Tm 
values corresponding to each peak is observed in the presence of increasing concentrations of compound. 
B, summary of the Tm data obtained by differential scanning fluorimetry in the presence of Benzopurpurin 
B (BP), Congo red (CR) and C-473872. A shift in the Tm values is indicative of binding to the compound 
to sNsp15. C, double reciprocal plot analysis for Benzopurpurin B, Congo red and C-473872. A change in 
the slope of the plots upon increasing inhibitor concentrations is characteristic of a competitive mechanism 
of inhibition. 
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The MHV and IBV Nsp15 Activity are Inhibited by Benzopurpurin B in vitro  
Coronaviruses can be important pathogens of animals as well as humans (9, 10, 
11).  Elucidation of the structure of the MHV Nsp15 (mNsp15) and molecular modeling 
revealed that the active site structure is highly similar to that of the SARS-CoV Nsp15 
(62, 64, Fig. 8A). We wanted to determine whether an inhibitor active against the SARS-
CoV Nsp15 will have similar effects on the Nsp15 proteins of other coronaviruses.  
Superimposition of sNsp15 docked with Benzopurpurin B on top of mNsp15 showed 
that Benzopurpurin-like inhibitors could be accommodated within the MHV Nsp15 
active site (Fig. 8A); the flexibility of the C-terminal active site can further augment the 
binding.  When tested for effects on RNA cleavage by the MHV Nsp15 protein 
expressed in E. coli, Benzopurpurin B was found to have an IC50 and IC90 of 0.4 and 0.9 
µM, highly similar to the values obtained with the SARS-CoV Nsp15 (Fig. 8B).   
To extend the analysis further, we tested the effects of Benzopurpurin B on the 
Nsp15 ortholog of infectious bronchitis virus (IBV), iNsp15, which was demonstrated by 
Bhardwaj et al. (2004) (47) to specifically cleave uridylates.  Since the iNsp15 structure 
has not been determined, we threaded its sequence into the crystal structure of the 
SARS-CoV. The active site of the protein was essentially comparable to that of the 
SARS-CoV and MHV orthologs and could accommodate Benzopurpurin B (Fig. 8C).  A 
prediction of this analysis is that the iNsp15 will also be inhibited by the compounds 
effective on the MHV and SARS-CoV Nsp15.  Indeed, the iNsp15 was inhibited by 
Benzopurpurin B in a concentration-dependent manner and with IC50 and IC90 values 
similar to that of the MHV and SARS-CoV Nsp15 enzymes (Fig. 8D).  These results 
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suggest that the Nsp15 orthologs from these three coronaviruses likely have highly 
similar active site pockets. Furthermore, it should be possible to use model 
coronaviruses to study the effects of these drugs on viral infection under conditions that 
do not require BSL3 containment. 
 
 
 
 
 
 
FIGURE 8. Inhibition of RNA cleavage in vitro in other coronavirus Nsp15 orthologs. A, a model for 
the binding of Benzopurpurin B in the MHV Nsp15 crystal structure (magenta ribbon and grey sticks; 
PDB ID 2gth). Althought the catalytic site residues are identical, the nearby residues are not conserved 
between sNsp15 and mNsp15, non-conserved residues are shown in parenthesis. Perhaps the flexibility of 
the C-terminal active site residues should enable the inhibitor binding to mNsp15 as well. B, effects of 
Benzopurpurin B on the MHV Nsp15 ortholog. The enzyme is inhibited in a concentration dependent 
manner. C, a model of the IBV Nsp15 ortholog. The active site residues in the IBV Nsp15 homology 
model are well conserved with the SARS-CoV Nsp15. D, Effects of benzopurpurin B on endoribonuclease 
activity of the IBV Nsp15 ortholog using the real-time fluorescence assay. 
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Inhibition of MHV Infection in Cultured Cells 
The effect of the compounds on MHV replication was investigated in plaque 
formation assays using mouse L2 cells. The cells were plated in six-well cell culture 
plates and grown until 100% confluence then infected with different dilutions of MHV 
A59 and the inhibitor at a final concentration of 100 µM. After a 1 h period to allow the 
infection to initiate, the cells were covered with a mixture of medium and agarose and 
incubated for two days, when the plaques were stained and scored. In three independent 
experiments, Congo red reproducibly showed the most inhibition of MHV plaque 
formation, with the mean reduction of plaque formation being 26-fold. Compound C- 
473872 caused an 11-fold reduction, and Benzopurpurin B, despite being the best 
inhibitor in vitro, resulted in an 8-fold reduction. None of the compounds had any 
obvious effect on the shape or viability of the cells when present at 100 µM (Fig. 9A, 9B 
and data not shown). 
To confirm and extend the analysis of the compounds on MHV infection, Dr. 
Kanchan Bhardwaj examined MHV RNA production in the presence of Benzopurpurin 
B, Congo red and C-473872. Genomic and subgenomic RNAs were reduced in the 
presence of the drugs, with C-473872 being the most effective and Benzopurpurin B 
having only a minimal effect in cells.  Furthermore, both the genomic and subgenomic 
MHV RNA levels were uniformly affected (Fig. 9C).  
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FIGURE 9. Effects of select Nsp15 inhibitors on MHV plaque formation in mouse L2 cells. A, 
representative plaque assay results in presence of Congo red and C-473872 at 100 uM, or controls such as 
the solvent DMSO. B, summary of the effects of the small-molecule compounds on MHV replication in 
L2 cells. The number of PFU/mL obtained and the fold reduction observed in three independent assays are 
reported. C, effects of the compounds on MHV RNA accumulation. The identities of the RNAs are shown 
to the left of the gel image. The rRNAs are intended to serve as a loading control. The result in panel C 
was obtained by Bhardwaj K. 
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DISCUSSION 
 
The development of both vaccines and anti-virals specific against coronavirus 
infections is currently a need.  The Nsp15 endoribonuclease is a genetic marker for 
coronaviruses and is an unusual enzyme for RNA viruses. Based on the observation that 
Nsp15 has an Ribonuclease A-like active site and a mechanism for RNA cleavage 
identical to Ribonuclease A (61, 64) we tested previously identified inhibitors of 
Ribonuclease A and Angiogenin, a Ribonuclease A-like enzyme. 
 Computational docking into the structure of sNsp15 predicted that small-
molecule inhibitors of Angiogenin and RNase A could bind to the Nsp15 active site. 
Functionally, three Angiogenin and RNase A inhibitors, C-473872, C-467929, 
Benzopurpurin B, and the structurally related Congo red, were found to be potent 
inhibitors of the sNsp15 endoribonuclease activity in vitro.  To put this into context, 
more than 50 candidates with high probability of docking into the sNsp15 active site 
were tested previously and no compounds were found to have IC50 values better than 50 
µM (Bhardwaj et al. unpublished data). Surprisingly, four inhibitors out of seven with 
IC50s of better than 10 µM were found. The results add a layer of functional relevance to 
the claims that sNsp15 has an RNase A-like catalytic pocket and cleavage mechanism 
for the Nsp15 of different coronaviruses (61, 64). 
 Benzopurpurin B, Congo red, and C-473872 were able to bind sNsp15 since 
they induce a concentration-dependent shift of the Tm of sNsp15. Benzopurpurin B and 
C-473872 induce an increase in the sNsp15 Tm that corresponds to a stabilizing effect of 
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the compounds. Interestingly, Congo red induces the Tm to decrease, suggesting that it 
destabilized the protein. Since Benzopurpurin B and C-473872 are active site inhibitors 
of RNase A and Angiogenin (69, 70), and Congo red is likely to be one as well, and the 
three compounds could bind to the sNsp15 active site according to computational 
docking models, it is logical to assume that these compounds are competitive inhibitors. 
The inhibition curves suggest this as well.  However, at the present time, we cannot rule 
out the presence of additional binding sites for these compounds in sNsp15.    
Benzopurpurin B showed to inhibit the MHV and IBV Nsp15 orthologs similarly 
to sNsp15, suggesting that the Nsp15 orthologs from these three coronaviruses likely 
have highly similar active site pockets, which supports previous structural and 
mutational studies of the mNsp15 (59, 62).  
Importantly, Congo red and C-473872 reduced the infection of MHV in cultured 
cells by several fold. The structures of these compounds should be considered as leads 
for subsequent development of coronavirus inhibitors. The best inhibitor in biochemical 
assays, Benzopurpurin B, was not particularly effective in virus-infected cells. This is 
likely due to pharmacological properties of Benzopurpurin B, like half-life in solution or 
in the cells or the ability to enter cells, features that we have not pursued in this work. 
Notably, the fact that Benzopurpurin B differed from Congo red only by the presence of 
two methyl groups indicates that small modifications to Congo red or Benzopurpurin B 
could have dramatic effects on the efficacy of these compounds in cells.   
Congo red is also a promising lead compound in the imaging and treatment of 
amyloid protein plaques (72, 73). Its ability to interact with nucleotide-binding enzymes 
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explains in part its efficacy to inhibit RNase A and Nsp15 (74). Congo red and its 
derivatives when administered near the time of infection have been shown to delay the 
onset of clinical disease in scrapie infected hamsters (75). However, Congo red is 
potentially toxic due to its degradation into the carcinogenic compound benzidine and 
several derivatives have been tested for anti-amyloid properties (76). These compounds 
would be of interest for testing its efficacy to treat coronavirus infections. 
The compounds can also serve as new tools to analyze coronavirus infection. A 
proposed role for Nsp15 is that it may participate in the processing of the RNAs needed 
to form coronavirus subgenomic RNAs (8).  However, there is no direct evidence for 
this in MHV. The compounds induced a reduction in the MHV RNA levels affecting 
uniformly genomic and subgenomic RNAs. In fact, mutational analysis of the mNsp15 
resulted in a general decrease in all MHV RNAs and an approximately one log decrease 
in MHV virion production. If Nsp15 does have a direct effect on subgenomic RNA 
production, the effects are sufficiently pleiotropic to affect all MHV RNAs (59). The 
effects of the inhibitors on MHV RNA production are consistent with those from 
previous mutational analyses (59). More judicious application of Congo red and C-
473872 at different stages of coronavirus infection in cultured cells could allow better 
insight into how Nsp15 contributes to this process.  
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CONCLUSIONS 
 
The Nsp15 endoribonuclease is a genetic marker for coronaviruses and is an 
unusual enzyme for RNA viruses which makes it a promising target for new antiviral 
therapies. 
Nsp15 active site and mechanism similarities to Ribonuclease A (61, 64) led us 
to test previously identified inhibitors of Ribonuclease A and Angiogenin, a 
Ribonuclease A-like enzyme. 
Computational docking into the structure of sNsp15 predicted that small-
molecule inhibitors of Angiogenin and RNase A could bind to the Nsp15 active site. 
Three Angiogenin and RNase A inhibitors, C-473872, C-467929, Benzopurpurin B, and 
the structurally related Congo red, were found to be potent inhibitors of the sNsp15 
endoribonuclease activity in vitro with IC50 of less than 10 µM. 
Benzopurpurin B, Congo red, and C-473872 were able to bind sNsp15 since they 
induce a concentration-dependent shift of the Tm of sNsp15. As predicted by the docking 
models they are active site inhibitors of sNsp15 according to double reciprocal analysis. 
Benzopurpurin B inhibited the MHV and IBV Nsp15 orthologs similarly to 
sNsp15, suggesting that the Nsp15 orthologs from these three coronaviruses likely have 
highly similar active site pockets, which supports previous structural and mutational 
studies of the mNsp15. 
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Congo red and C-473872 reduced the infection of MHV in cultured cells by 
several fold. The structures of these compounds should be considered as leads for 
subsequent development of coronavirus inhibitors. 
The compounds induced a reduction in the MHV RNA levels affecting uniformly 
genomic and subgenomic RNas.  
The compounds can also serve as new tools to analyze coronavirus infection. 
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